Ipsen Sa · EURONEXT:IPN
Ipsen Sa — Jefferies Healthcare Conference 2015
18 slides from Ipsen Sa's conference presentation, November 2015
Slide 1: Ipsen Jefferies Healthcare Conference
Ipsen Jefferies Healthcare Conference November 2015 IPSEN pour nom de la société - 07/04/2011 / page 1
Slide 2: Disclaimer and Safe Harbor
Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements involve known an
Slide 3: Agenda
Agenda 1 Strategic update 2 2015 performance and outlook 3 Ipsen – 2015 Jefferies Healthcare Conference 3 Goldman Sachs 35th Annual Global Healthcare Conference – June 2014
Slide 4: Strategic update
Strategic update
Slide 5: An increasing weight of specialty care and of the US
An increasing weight of specialty care and of the US 9M 2015 sales by segment 9M 2015 sales by geography Top 5 affiliates Primary Emerging 1 France care markets Europe ~23% 38% G5 38% 2 China ~77% 3 US Specialty 10% care 14% 4 Germany Developed US RoW 5 Italy One of the largest emerging market prese
Slide 6: A refocused strategy within specialty and primary care
A refocused strategy within specialty and primary care Global leadership in targeted diseases Focus on GI/OTx Focus on NET/spasticity/Dysport® aesthetics Optimize the GI portfolio (Galderma) Diversify into adjacent GI pathologies Reinforce position in uro-oncology/adult endocrinology Reinf
Slide 7: 2020 outlook showing strong sales growth and profitability momentum
2020 outlook showing strong sales growth and profitability momentum Group organic sales Core Operating margin(1) >+560bps [+6% to +8%] CAGR > 26% [€1.8bn to €2bn] 20.4% €1.3bn 2014 2020 E 2014 2020 E Potential Business Development to complement €1.8bn to €2.0bn organic sales target 7 Ipsen – 2015 Je
Slide 8: Turnaround of the US platform, with high potential for growth
Turnaround of the US platform, with high potential for growth US affiliate sales growth(1) Somatuline® US sales growth 103.3% 50.7% 31.2% 28.6% 18.6% 11.5% 2013 2014 9M 2015 2013 2014 9M 2015 US affiliate to reach breakeven ahead of plan and drive significant profitability increase thanks to Somatul
Slide 9: Somatuline accelerated NET penetration in the US and Europe
Somatuline® accelerated NET penetration in the US and Europe Somatuline® US quarterly data, all indications Somatuline® Europe G5(1) quarterly data, all indications sales ($m) market share (%) sales (€m) market share (%) 36 10 45 32 9 37 28 8 40 24 7 20 6 27 35 16 5 30 12 4 17 8 3 25 4 2 0 1 7 20 Q3
Slide 10: Major R&D and regulatory milestones
Major R&D and regulatory milestones H1 2015 H2 2015 2016 Dysport® PLL PhIII topline results Telotristat etiprate (LX1032) PhIII results OPS202 Ph3 initiation R&D Dysport® ALL PhIII topline results OPS201 Ph1 initiation Syntaxin compound Ph1 initiation DNG positive regulatory feedback Dysport
Slide 11: Exclusive license agreement with Telesta for NMIBC treatment
Exclusive license agreement with Telesta for the treatment of non-muscle invasive bladder cancer (NMIBC) NMIBC1 Treatment 2nd / 3rd line option post BCG2 treatment for high risk NMIBC1 BCG FDA PDUFA3 date: 27 February 2016. Regulatory 1st line treatment pathway to be discussed for Europe. Excl
Slide 12: 2015 performance and outlook
2015 performance and outlook
Slide 13: 9M 2015 – Steady Specialty care growth
9M 2015 – Steady Specialty care growth Drug sales – 9M 2015 in million euros – % excluding foreign exchange impact ® Somatuline +30.7% 292 ® Decapeptyl (1.6%) Specialty care Specialty care 251 ® €824.5m Dysport +5.2% 209 +10.9% Nutropin ® +0.2% 46 ® Group sales Increlex 14 +49.7% €1,068.3m Hexvix ®
Slide 14: Core Operating margin H1 2015 evolution
Core Operating margin H1 2015 evolution In million euros Total other FX Products(1) Somatuline® US Sales 639 714 H1 2014 H1 2015 COI Margin (as % of sales) 25.4% -1.4% -0.1% -0.4% 23.5% Somatuline® US investment dilutive to Group margin in H1 2015 Note: COI=Core Operating Income 14 Ipsen – 2015 Jeff
Slide 15: H1 2015 cash flow generation
H1 2015 cash flow generation In million euros Free cash flow: €26m(1) Operating Change in cash working flow(1) capital(2) -94 +139 Capex Opening Dividends -19 cash Share External -70 Buyback acquisitions Closing -4 -37 Other cash 180 -7 88 31 Dec 2014 30 June 2015 Solid free cash flow generation Clo
Slide 16: 2015 guidance confirmed showing strong sales and profitability momentum
2015 guidance confirmed showing strong sales and profitability momentum Group organic sales Core Operating margin(1) ≥+160bps ≥+9.5%(2) ≥ €1.40 bn(3) ≥ 22% €1.27bn 20.4% 2014 2015 E 2014 2015 E Sales growth and profitability driven in 2015 by the success of Somatuline® launch (1) In percentage of sa
Slide 17: Key 2015 achievements
Key 2015 achievements Solid Operating performance driven by Specialty sales growth Accelerated Somatuline® momentum with significant US launch investment Readiness for US launch of Dysport® in AUL spasticity after July FDA approval Continued business development efforts with acquisition of Canbex, O
Slide 18: Thank you
Thank you